Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Arcutis today announced the enrollment of the last subject in the Phase 1b study evaluating ARQ-255 for the treatment of alopecia areata.
-
Arcutis today announced results from the INTEGUMENT-OLE long-term open-label study of once-daily roflumilast cream 0.05%.
-
Arcutis today announced that management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
-
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
-
Arcutis today reported financial results for the quarter ended June 30, 2024, and provided a business update.
-
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
-
Arcutis today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024.
-
Arcutis today announced the signing of a co-promotion agreement with Kowa Pharmaceuticals America, Inc.
-
Arcutis today announced the commercial launch of ZORYVE® (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis.
-
Arcutis today announced the submission of an sNDA in scalp and body psoriasis.